Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2023 13:41 ET | Source: Psycheceutical Bioscience, Inc.

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab

Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical"...
March 21, 2023 12:50 ET | Source: Psycheceutical Bioscience, Inc.

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD

A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical...
February 15, 2023 11:30 ET | Source: Psycheceutical Bioscience, Inc.

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD

Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical in AustraliaPhase I trial will study 20 people to test the safety, tolerability,...
February 02, 2023 10:20 ET | Source: Psycheceutical Bioscience, Inc.

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery...
January 26, 2023 12:15 ET | Source: Psycheceutical Bioscience, Inc.

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for...
January 10, 2023 14:05 ET | Source: Psycheceutical Bioscience, Inc.

Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer

MIAMI, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc.(OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery...
November 29, 2022 11:35 ET | Source: Psycheceutical Bioscience, Inc.

Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director

MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...
October 18, 2022 10:15 ET | Source: Psycheceutical Bioscience, Inc.

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

MIAMI, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...
October 04, 2022 10:14 ET | Source: Psycheceutical Bioscience, Inc.

Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council

MIAMI, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...
September 13, 2022 11:15 ET | Source: Psycheceutical Bioscience, Inc.

Psycheceutical Bioscience, Inc.'s CEO to Present at the Life Sciences Investor Forum on September 15

MIAMI, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...

Next Page keyboard_arrow_right